ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1465

Blood-dominant Disease in Older-onset Lupus: A Systematic Review and Meta-analysis

Sarah Abi Doumeth1, Marina Nighat Magrey2 and Omer Pamuk3, 1Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH, 2Case Western Reserve University, University Hospitals, Cleveland, OH, 3University Hospitals Cleveland Medical Center, Cleveland, OH

Meeting: ACR Convergence 2023

Keywords: meta-analysis, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 13, 2023

Title: (1442–1487) SLE – Diagnosis, Manifestations, & Outcomes Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Previous studies have shown that the clinical manifestations of systemic lupus erythematosus (SLE) differ based on age of onset. Late onset SLE has been shown to be milder, with lower frequency of lupus nephritis, cutaneous and neuropsychiatric presentations however with more prevalent pulmonary manifestations. There have been multiple retrospective or prospective studies comparing hematological manifestations in early-onset SLE patients (age< 50) with older onset SLE patients (age >50) with varying results. We performed a systematic review and meta-analysis to evaluate the differences in hematologic manifestations (autoimmune hemolytic anemia(AIHA),thrombocytopenia(TP), lymphopenia, leukopenia, lymphadenopathy and thrombosis) in late-onset SLE patients (ltSLE) compared to adult-onset SLE patients (aSLE).

Methods: Literature search was performed using PubMed, Web of Science and Cochrane Library. PRISMA 2020 guidelines and checklist were used. Studies were included if they investigated the frequency of hematological manifestations in ltSLE patients and excluded if they did not include aSLE as control group. The diagnosis of SLE was performed with ACR 1997 revised classification criteria for SLE. We included cohort, case-control, and population-based studies. Two authors independently reviewed all articles and evaluated the data for consistency between the abstracts, tables, and text to avoid a bias. Forest plot was used to compare odds ratios (95% CI) of hematological manifestations by age groups. Study heterogeneity was assessed using I2.All analyses were performed using R Statistical Software meta package (v4.2.1; R Core Team 2022).

Results: 44 eligible studies comprising 20,508 SLE patients (17421 aSLE and 3087 ltSLE) were included in analysis. Among these studies, 27 reported the occurrence of AIHA which was found to be more frequent in the aSLE group compared to ltSLE (OR: 1.36, 95% CI: 1.15-1.61, p=0.0003) (Figure 1). Further analysis of 40 studies revealed a higher frequency of TP in the aSLE group (OR: 1.16, 95% CI: 1.05-1.28, p=0.0045) (Figure 2). 19 studies provided data on lymphopenia which was found to be more frequent in aSLE (OR: 1.16, 95%CI: 1.04-1.30, p=0.0082) (Figure 3). 31 studies included data for leukopenia and the frequency was higher in the aSLE (OR: 1.28, 95% CI: 1.17-1.41). Additionally, lymphadenopathy was more commonly seen in aSLE group (OR: 2.18, 95%CI: 1.47-3.24, p=0.0001). However, no significant difference was observed in the frequency of thrombosis between the two groups.

Conclusion: Attributing hematological findings to SLE may be challenging in older onset patients due to comorbidities and polypharmacy. In this study, the overall frequencies of AIHA, TP, lymphopenia, leukopenia and lymphadenopathy were more common in aSLE patients compared to ltSLE.

Supporting image 1

Figure 1. Odd ratios for AIHA in early and late onset SLE patients

Supporting image 2

Figure 2. ORs for TP in early and late onset lupus groups.

Supporting image 3

Figure 3. ORs for lymphopenia in aSLE and ltSLE patients.


Disclosures: S. Abi Doumeth: None; M. Magrey: AbbVie, 2, Bristol Myers Squibb, 2, Eli Lilly, 2, Novartis, 2, Pfizer Inc, 2, UCB, 5; O. Pamuk: None.

To cite this abstract in AMA style:

Abi Doumeth S, Magrey M, Pamuk O. Blood-dominant Disease in Older-onset Lupus: A Systematic Review and Meta-analysis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/blood-dominant-disease-in-older-onset-lupus-a-systematic-review-and-meta-analysis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/blood-dominant-disease-in-older-onset-lupus-a-systematic-review-and-meta-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology